PT  - JOURNAL ARTICLE
AU  - Wijsenbeek, Marlies S.
AU  - Spagnolo, Paolo
AU  - Kolb, Martin
AU  - Kreuter, Michael
AU  - Nunes, Hillario
AU  - Stansen, Wibke
AU  - Rohr, Klaus
AU  - Inoue, Giichi
TI  - Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)?
AID  - 10.1183/13993003.congress-2021.PA3748
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3748
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA3748.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA3748.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Background: The INBUILD trial enrolled patients with progressive fibrosing ILDs other than IPF. It is unclear whether, as observed in patients with IPF, patients with fibrosing ILDs who have worse scores on patient-reported outcomes assessing symptoms or health-related quality of life (HRQL) are at greater risk of ILD progression.Aim: To assess associations between patient-reported outcomes at baseline and progression of fibrosing ILDs in the INBUILD trial.Methods: Associations between the King's Brief ILD (K-BILD) questionnaire total score and Living with Pulmonary Fibrosis (L-PF) questionnaire symptoms dyspnoea domain score at baseline and time to ILD progression (absolute decline in FVC ≥10% predicted) or death during the INBUILD trial were assessed using Cox’s regression models.Results: At baseline, mean (SD) K-BILD total and L-PF symptoms dyspnoea domain scores were 52.4 (10.5) (n=662) and 21.7 (18.0) (n=652), respectively, on scales of 0–100. Median exposure to trial drug was 17.4 months. In both treatment groups, baseline K-BILD total scores or L-PF symptoms dyspnoea domain scores that indicated worse HRQL were associated with a higher risk of ILD progression or death during the trial (Figure).Conclusions: In patients with progressive fibrosing ILDs, worse scores on patient-reported outcomes are associated with a higher risk of ILD progression or death. FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3748.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).